Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG)

Annals of Oncology : Official Journal of the European Society for Medical Oncology
A GoldhirschR D Gelber

Abstract

The first reported effective adjuvant combination regimen for patients with operable breast cancer comprised oral cyclophosphamide (C) days 1-14 with intravenous methotrexate (M) and fluorouracil (F) on days 1 and 8, repeated every 28 days ('classical' CMF). These drugs have since been extensively used with or without endocrine therapies and/or other cytotoxics, as well as with radiation therapy to the chest wall yielding conflicting results. Although doses and schedules have varied widely, the combination of these three drugs has been generically referred to as CMF. Evidence exists that reducing the dose and/or altering the schedule of CMF ('modified' CMF) have compromised its efficacy in metastatic breast cancer. Reduction below standard dose of a similar regimen also gave inferior results in the adjuvant setting. In fact, the recently reported improved outcome of adding radiation therapy to CMF was only demonstrated in comparisons with a 'modified' CMF. Furthermore, trials in women with estrogen receptor-positive breast cancer, which did not demonstrate any significant benefit for the addition of adjuvant CMF to tamoxifen compared with tamoxifen alone, also used 'modified' CMF. Therefore, adherence to the 'classical' dose an...Continue Reading

Citations

Sep 18, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A GoldhirschH J Senn
Jul 9, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aron GoldhirschHans-Jörg Senn
May 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Ozsahin
Sep 30, 2006·Cancer Chemotherapy and Pharmacology·Garth A BeinartG N Hortobagyi
Apr 5, 2007·Journal of the National Cancer Institute·UNKNOWN Adjuvant Breast Cancer Trials Collaborative Group
Apr 26, 2003·The Breast Journal·Robert W CarlsonUNKNOWN Global Summit Treatment Panel
Aug 26, 2009·Women's Health·Sumanta Kumar Pal, Joanne Mortimer
Jan 25, 2006·The Breast Journal·Alexandru EniuUNKNOWN Global Summit Treatment and Allocation of Resources Panel
Nov 3, 2006·The New England Journal of Medicine·Christopher J PooleUNKNOWN NEAT Investigators and the SCTBG
Jan 1, 2015·Journal of Translational Internal Medicine·Alexandru C Grigorescu
Mar 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angelo Di Leo, Marc Buyse
Dec 10, 2009·Nature Reviews. Clinical Oncology·Philippe L BedardMartine J Piccart-Gebhart
Aug 19, 2008·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Xinran XuJia Chen
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A WallgrenUNKNOWN International Breast Cancer Study Group Trials I through VII
Dec 19, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W JonatUNKNOWN Zoladex Early Breast Cancer Research Association Study
Jul 1, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E MunzoneA Goldhirsch
Dec 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K J RuddyA H Partridge

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.